Clinical trials: Plaque Psoriasis Subjects
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Moderate Plaque Psoriasis
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen).
- Trial name
- IMMpactful (NCT06333860)
- Testing
- Risankizumab, Deucravacitinib
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 393 people
- Sponsor
- AbbVie
Psoriasis
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01937260
- Testing
- Brodalumab
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
A Phase 3 Clinical Study of KHK4827
This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.
- Trial name
- NCT01782924
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 145 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and…
- Trial name
- NCT03255382
- Testing
- Fumaderm, risankizumab
- Where
- 23 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AbbVie
Psoriasis
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06672393
- Testing
- HS-10374 6mg tablets
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Hansoh BioMedical R&D Company
Plaque Psoriasis
Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis
This is a 16-week, prospective, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate psoriasis treated with ANM.
- Trial name
- NCT03817164
- Testing
- Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Thync Global, Inc.
Plaque Psoriasis
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and…
- Trial name
- NCT01698333
- Testing
- 122-0551
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Therapeutics, Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE BRIGHT (NCT03598790)
- Testing
- Bimekizumab
- Where
- 189 sites in United States, Australia and 11 more
- Volunteers
- 1,353 people
- Sponsor
- UCB Biopharma SRL
Psoriasis Vulgaris
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics profiling for further investigation.
- Trial name
- NCT03795402
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Immunomodulation
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics.
- Trial name
- NCT01736696
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Pfizer
Psoriasis
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
- Trial name
- NCT01878461
- Testing
- Vehicle, M518101
- Where
- 34 sites in United States
- Volunteers
- 542 people
- Sponsor
- Maruho North America Inc.
Plaque Psoriasis
Clinical Study of Stage IV Psoriasis in Children With Geleli
This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study.
- Trial name
- NCT05803187
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bio-Thera Solutions
Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
- Trial name
- NCT02785185
- Testing
- IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion
- Where
- 13 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
- Trial name
- NCT04128007
- Testing
- Roflumilast foam 0.3%, Vehicle foam
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 304 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease…
- Trial name
- NCT02295865
- Testing
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg
- Where
- 13 sites in United States, Poland
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC